scientific and microscope

Our clinical studies

We are committed to make our Clinical trials Information and Results accessible and transparent while maintaining participants privacy.

 

Clinical studies

This site provides information on both ongoing and completed clinical trials sponsored by Pierre Fabre since 2004. Real-world evidence studies which began after 01 January 2020 are also accessible.

 

Total studies

0

Current studies

0

Oncology

0

Dermatology

0

Rare diseases

0

Others

0
Show more filters
Title Therapeutic area Phase Status Start date (Planned) End date

A multicenter, open-label, phase 1 study investigating the safety and tolerability of encorafenib monotherapy in BRAFV600E-mutated Chinese patients with advanced metastatic solid tumors

Oncology Phase I Completed September 15, 2021 May 06, 2022

Frequency and Intensity of local reactions in patients treated with 4% 5-FU vs 4% 5-FU associated with an emollient cream: a randomised, controlled clinical trial

Dermatology Phase IV Completed February 16, 2021 January 31, 2022

A retrospective non interventional study on first line treatment for patientswWith BRAF V600E mutant metastatic colorectal cancer (mCRC) (CAPSTAN CRC)

Oncology RWE Completed April 12, 2020 December 05, 2021

Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.

Oncology Phase I / II Completed November 24, 2017 October 04, 2021

Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer

Oncology Phase II Completed August 03, 2015 September 28, 2020

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Oncology Phase II Completed March 2004 May 21, 2019

Study of efficacy and safety of V0305 solution in children suffering from Iron Deficiency Anaemia (IDA). Phase 3, multicentre, single arm open-label study

Blood Disorders Phase III Completed June 06, 2016 January 24, 2019

Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based chemotherapy (study L00070 IN 309 F0)

Oncology Phase III Completed April 02, 2012 November 23, 2018

Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

Oncology Phase II Completed October 26, 2015 October 15, 2018

Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer

Oncology Phase II Completed October 04, 2012 September 05, 2018

Evaluation of erectyle disfonction in patients suffering from testosterone deficiency, before and after tretament by Testopatch

Hormonal Phase IV Early termination October 16, 2007 May 02, 2018

Phase III study of Vinflunine plus Capecitabine versus Capecitabine alone in patients with advanced breast cancer

Oncology Phase III Completed September 2013 July 2017

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure

Cardiovascular Phase II Completed May 20, 2013 June 21, 2017

Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcitabine in first line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type

Oncology Phase II Completed December 01, 2012 May 19, 2017

Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia

Oncology Phase I / II Early termination April 09, 2013 March 03, 2017

Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational single arm study

Dermatology Phase III Completed June 29, 2015 February 21, 2017

Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma

Oncology Phase III Early termination February 22, 2016 January 08, 2017

Effects of F17464 in acute exacerbation of schizophrenia

Psychiatry Phase II Completed August 20, 2014 November 23, 2016

Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence

Respiratory Phase III Completed September 02, 2013 October 17, 2016

PERMIXON® 160 mg hard capsule versus placebo in the treatment n the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia

Urology Phase IV Completed May 07, 2014 June 27, 2016

Get access to Partner's pivotal studies supporting our authorized drugs in Europe

Results from pivotal studies conducted by our partners and supporting a marketing approval for whom Pierre Fabre is the holder in Europe are shared below:

 

Melanoma

SPONSOR: PFIZER

Breast cancer 

SPONSOR: PUMA BIOTECHNOLOGY

Colorectal cancer

SPONSOR: PFIZER

Post-transplantation lymphoproliferative disease EBV+

SPONSOR: ATARA